Molecular staging of malignant melanoma: Correlation with clinical outcome

JAMA

Volumn 280, Issue 16, 1998, Pages 1410-1415

  Shivers, Steven C ^a,b   Wang, Xiangning ^a,b   Li, Weiguo ^a,b   Joseph, Emmanuella ^a,b   Messina, Jane ^a,c   Glass, L Frank ^a,c   DeConti, Ronald ^a,b   Cruse, C Wayne ^a,b   Berman, Claudia ^a,b   Fenske, Neil A ^a,b   Lyman, Gary H ^b   Reintgen, Douglas S ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; TECHNETIUM SULFUR COLLOID TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; TREATMENT OUTCOME;

EID: 0032576140     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.16.1410     Document Type: Article

References (36)

1. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel node in a feline model. Ann Surg. 1991;214:637-641.
2. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
3. Balch C, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-266.
4. Ross MI, Reintgen DS, Balch C. Selective lymph-adenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early melanoma. Semin Surg Oncol. 1993;9:219-223.
5. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining lymph node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993;34:1435-1440.
6. Reintgen DS, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-767.
7. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg. 1995;130:654-658.
8. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in lymph nodes of patients with pathological stage I melanoma. Am J Surg Pathol. 1988;12:612-618.
9. Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer. 1990;66:765-771.
10. Walts AE, Said JW, Shintaku IP. Cytodiagnosis of malignant melanoma: immunoperoxidase staining with HMB-45 antibody as an aid to diagnosis. Am J Clin Pathol. 1988;90:77-80.
11. Morena JG, Crose CM, Fisher R, et al. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res. 1992;52:6110-6112.
12. Wood DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol. 1997:15:3451-3457.
13. Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991;324:219-226.
14. Roberts WM, Estrov Z, Ouspenskaia MV, et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997;336:317-323.
15. Fields KK, Elfenbein GJ, Trudeau WL, et al. Clinical significance of bone marrow metastases detected using the polymerase chain reaction in patients with breast cancer undergoing high dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol. 1996;6:1868-1876.
16. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol. 1996;148:649-656.
17. Wang X, Heller R, Van Voorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994;220:768-774.
18. Maehara Y, Oshiro T, Endo K, et al. Clinical significance of occult micrometastases in lymph nodes from patients with early gastric cancer who died of recurrence. Surgery. 1996;119:397-402.
19. Greenson JK, Isenhart CE, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49: correlation with long term survival. Cancer. 1994;73:563-569.
20. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188-1194.
21. Norman J, Cruse CW, Wells K, Berman C, Clark R, Reintgen DS. A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432-437.
22. Berman C, Norman J, Cruse CW, Reintgen DS, Clark RA. Lymphoscintigraphy in malignant melanoma. Ann Plast Surg. 1992;28:29-32.
23. Veronesi U, Cascinelli N, Adamus J, et al. Primary cutaneous melanoma 2 mm or less in thickness: results of a randomized study comparing wide with narrow surgical excision: a preliminary report. N Engl J Med. 1988;318:1159-1162.
24. Balch CH, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm): results of a multiinstitutional randomized surgical trial. Ann Surg. 1993;218:262-267.
25. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith T, Borden E, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
26. Messina J, Glass F. Pathologic examination of the sentinel lymph node. J Fla Med Assoc. 1997;84: 153-156.
27. Kwon BS, Haq AK, Pomerantz SH, Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci U S A. 1987;84:7473-7477.
28. Kaplan EL, Meier P. Nonparametricestimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
30. Cox D. Regression models and lifetables. J R Stat Soc B. 1972;34:187-201.
31. Reintgen DS, Vollmer R, Tso CV, Seigler HF. Prognosis for stage I malignant melanoma. Arch Surg. 1987;122:1338-1342.
32. Breslow A. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
33. Balch CM, Cascinelli N, Drewiecki KT, et al. A comparison of prognostic factors world-wide. In: Balch CM, Houghton AN, Milton GW, Sober A, Soong S-J, eds. Cutaneous Melanoma. 2nd ed. Philadelphia, Pa: JB Lippincott; 1992:188.
34. Heller R, Becker J, Wasselle J, et al. Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg. 1991;126:1455-1460.
35. Heller R, King B, Baekey P, Cruse W, Reintgen D. Identification of submicroscopic lymph node metastases in patients with malignant melanoma. Semin Surg Oncol. 1993;9:285-289.
36. Gershenwald J, Colome MI, Mansfield P, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-2260.